PRCT 33.00 ▲ 0.24% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    PROCEPT BioRobotics Corpo...

    NASDAQ: PRCT · Real-Time Price · USD
    33.00
    0.08 (0.24%)
    At close: Oct 13, 2025, 3:59 PM
    32.84
    -0.48%
    Pre-market: Oct 14, 2025, 06:29 AM EDT
    0.24%
    Bid 32.46
    Market Cap 1.84B
    Revenue (ttm) 274.95M
    Net Income (ttm) -84.14M
    EPS (ttm) -1.54
    PE Ratio (ttm) -21.43
    Forward PE -33.59
    Analyst Buy
    Dividends n/a
    Ask 33.53
    Volume 921,703
    Avg. Volume (20D) 1,201,128
    Open 33.06
    Previous Close 32.92
    Day's Range 32.46 - 33.69
    52-Week Range 32.46 - 103.81
    Beta 0.99
    Ex-Dividend Date n/a

    About PRCT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PRCT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PRCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    PROCEPT BioRobotics Corporation is scheduled to release its earnings on Oct 27, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    -13.35%
    PROCEPT BioRobotics shares are trading lower follo... Unlock content with Pro Subscription
    2 months ago
    -5.05%
    PROCEPT BioRobotics shares are trading lower following the release of its Q2 financial results.
    news image

    1 week ago · seekingalpha.com

    Procept BioRobotics: A Strong Challenger Positioned To Be A Future Leader

    PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indic...

    news image

    1 month ago · 247wallst.com

    3 AI Growth Stocks to Turn $10K Into $50K in Short Order

    It is tempting to believe the next Nvidia (NASDAQ:NVDA ) or Palantir (NASDAQ:PLTR ) is hiding in plain sight and will quickly give you multibagger returns.

    news image

    2 months ago · seekingalpha.com

    Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy

    Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install...

    news image

    2 months ago · seekingalpha.com

    PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript

    PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Ma...

    news image

    2 months ago · fool.com

    Procept (PRCT) Q2 Revenue Jumps 48%

    Procept BioRobotics (PRCT -5.28%), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on August ...

    news image

    2 months ago · zacks.com

    PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates

    PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.5 per share a year ago.

    news image

    2 months ago · fool.com

    PROCEPT BioRobotics (PRCT) Earnings Transcript

    Image source: The Motley Fool.

    news image

    2 months ago · zacks.com

    Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know

    PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Add to Watchlist